These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27957778)

  • 21. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
    Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
    J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.
    Lum SS; Chua HW; Li H; Li WF; Rao N; Wei J; Shao Z; Sabapathy K
    Carcinogenesis; 2008 Apr; 29(4):754-61. PubMed ID: 18281248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
    Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
    Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults.
    Onel KB; Huo D; Hastings D; Fryer-Biggs J; Crow MK; Onel K
    Lupus; 2009 Jan; 18(1):61-6. PubMed ID: 19074170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
    Wang ML; Xu YX; Qian J; Wang FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
    Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
    Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.
    Khan SA; Idrees K; Forslund A; Zeng Z; Rosenberg S; Pincas H; Barany F; Offit K; Laquaglia MP; Paty PB
    J Surg Oncol; 2008 Jun; 97(7):621-5. PubMed ID: 18381604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
    Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
    BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.
    Do TN; Ucisik-Akkaya E; Davis CF; Morrison BA; Dorak MT
    Cancer Genet Cytogenet; 2009 Nov; 195(1):31-6. PubMed ID: 19837266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.
    Jamshidi M; Schmidt MK; Dörk T; Garcia-Closas M; Heikkinen T; Cornelissen S; van den Broek AJ; Schürmann P; Meyer A; Park-Simon TW; Figueroa J; Sherman M; Lissowska J; Keong GT; Irwanto A; Laakso M; Hautaniemi S; Aittomäki K; Blomqvist C; Liu J; Nevanlinna H
    Int J Cancer; 2013 May; 132(9):2044-55. PubMed ID: 23034890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese.
    Xu B; Xu Z; Cheng G; Min ZC; Mi Y; Zhang ZZ; Tao J; Li PC; Wang ML; Tang JL; Zhang ZD; Zhang W; Wu HF; Feng NH; Hua LX
    Cancer Genet Cytogenet; 2010 Oct; 202(2):76-81. PubMed ID: 20875869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women.
    Singh V; Rastogi N; Mathur N; Singh K; Singh MP
    Ann Epidemiol; 2008 Jan; 18(1):48-57. PubMed ID: 17719241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.